Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Delos Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 16
Average round size
info
The average size of a deal this fund participated in
$13M
Portfolio companies 6
Rounds per year 1.60
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.06
Key employees 4
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Biopharma
Summary

Delos Capital is the famous VC, which was founded in 2013. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the New York.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Delos Capital, startups are often financed by ONSET Ventures, New Enterprise Associates, Lumira Ventures. The meaningful sponsors for the fund in investment in the same round are Quadrille Capital, New Enterprise Associates, Lumira Ventures. In the next rounds fund is usually obtained by Square 1 Bank, Questa Capital Management, Quadrille Capital.

We also calculated 8 valuable employees in our database.

Among the most popular portfolio startups of the fund, we may highlight BAROnova, Curamir Therapeutics, OncoMyx Therapeutics. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular fund investment industries, there are Medical, Wellness.

The fund is generally included in less than 2 deals every year. The real fund results show that this VC is 42 percentage points more often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Delos Capital works on 16 percentage points less the average amount of lead investments. The important activity for fund was in 2019. The higher amount of exits for fund were in 2016.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Allianz France France, Ile-de-France, Puteaux
Being Group Japan, Tokyo
Comba Telecom Systems Holdings China, Hong Kong, New Territories
Haruyama Holdings Japan, Okayama, Okayama Prefecture
HZTi China, Hangzhou, Zhejiang
Mugar Enterprises Boston, Massachusetts, United States
Oakland County -
SmileGate Kyonggi-do, Seongnam, South Korea
String Ventures California, San Francisco, United States
Tongzhe Investment Management China, Hangzhou, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Exsilio Therapeutics

$82M25 Jun 2024 Boston, Massachusetts, United States

Ostial Corporation

Health Care
Manufacturing
Medical
$7M16 Sep 2022 Campbell, California, United States

Antios Therapeutics

Biopharma
Biotechnology
Therapeutics
$96M12 Apr 2021 Atlanta, Georgia, United States

Biotechnology
Therapeutics
$10M23 Sep 2019 Woburn, Massachusetts, United States

Antios Therapeutics

Biopharma
Biotechnology
Therapeutics
$25M27 Nov 2018 Atlanta, Georgia, United States

LipoSeuticals

Biotechnology
Health Care
Pharmaceutical
29 Jun 2017 Monmouth Junction, New Jersey, United States

Atia Vision

Biotechnology
Health Care
Medical
Medical Device
$3M12 May 2015 California, United States
News
Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care

– Imperative Care, Inc. announced that it has closed a $260m Series D financing led by D1 Capital Partners.
– New investors HealthCor Investments LLC and Innovatus Capital Partners also joined the round. Existing Imperative Care investors Ally Bridge Group, Bain Capital Life Sciences, Ascension Ventures, Delos Capital, Rock Springs Capital, and Amed Ventures participated in the financing.
– James Rogers from D1 will join Imperative Care’s Board of Directors.
– Proceeds from the financing will be used to support ongoing commercialization and development of a wide range of Imperative Care’s technologies in the broad continuum of stroke care, as well as to create a strategic network of wholly owned development subsidiaries in a number of areas of synergy.

Antios Therapeutics Raises $96M in a Series B

– Antios Therapeutics from San Diego, CA announced the successful completion of a $96m Series B financing.
– The financing was led by Soleus Capital with participation from new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as other healthcare focused funds, Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participation from all of the original Series A investors including Lumira Ventures, CAM Capital, Delos Capital, Domain Associates and Sixty Degree Capital.
– Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Delos Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 16
Average round size 13M
Rounds per year 1.60
Peak activity year 2015
Lead investments 4
Follow on index 0.06
Group Appearance index 0.88

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Exsilio Therapeutics

$82M25 Jun 2024 Boston, Massachusetts, United States

Ostial Corporation

Health Care
Manufacturing
Medical
$7M16 Sep 2022 Campbell, California, United States

Antios Therapeutics

Biopharma
Biotechnology
Therapeutics
$96M12 Apr 2021 Atlanta, Georgia, United States

Biotechnology
Therapeutics
$10M23 Sep 2019 Woburn, Massachusetts, United States

Antios Therapeutics

Biopharma
Biotechnology
Therapeutics
$25M27 Nov 2018 Atlanta, Georgia, United States

LipoSeuticals

Biotechnology
Health Care
Pharmaceutical
29 Jun 2017 Monmouth Junction, New Jersey, United States

Atia Vision

Biotechnology
Health Care
Medical
Medical Device
$3M12 May 2015 California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: